Selepressin

Summary

Selepressin is an investigational peptide that selectively activates the vasopressin V1A receptor. It is being studied as a non‑adrenergic vasopressor for patients with vasodilatory shock, particularly septic shock, where it may help raise blood pressure and reduce the need for high‑dose catecholamines such as norepinephrine.

Mechanism of Action

Selepressin binds with high affinity to the V1A (AVPR1a) receptor on vascular smooth‑muscle cells, triggering phospholipase C activation, intracellular calcium release and potent vasoconstriction. By acting through this non‑adrenergic pathway, it can increase systemic vascular resistance and mean arterial pressure while potentially sparing catecholamine use and limiting catecholamine‑related tachycardia or metabolic effects.

What the Research Shows

Systematic reviews and meta‑analyses of randomized trials have grouped selepressin with other non‑adrenergic vasopressors (vasopressin, terlipressin, angiotensin II). pooled data show non‑adrenergic agents reduce mortality in septic shock, but no individual agent, including selepressin, reached statistical significance when analyzed alone. A 2020 review identified only one controlled trial of selepressin, reporting that it raised MAP similarly to catecholamines but providing limited mortality or safety data. A 2022 perspective highlighted its ability to lower norepinephrine requirements, yet emphasized the scarcity of robust human evidence and the need for further trials.

Reported Benefits

Available data suggest selepressin can increase mean arterial pressure comparable to traditional catecholamines and may allow reduction of norepinephrine doses, which could lessen catecholamine‑related side effects. In pooled analyses of non‑adrenergic vasopressors, mortality was modestly lower in septic shock, indicating a possible benefit for agents like selepressin, though direct proof for this compound is lacking.

Limitations of the Evidence

Evidence for selepressin is limited to a single small trial and several pre‑clinical studies; most reviews describe the data as low quality with unclear risk of bias. No trial has demonstrated a statistically significant mortality advantage for selepressin alone, and safety signals such as digital ischemia remain unquantified. Consequently, its clinical role remains investigational.

Safety Considerations

Reports from broader analyses of vasopressin analogues note an increased risk of digital or peripheral ischemia with V1A agonists, including selepressin. General vasopressor adverse effects—excessive vasoconstriction, organ ischemia, and metabolic disturbances—apply, and caution is advised when used in patients with compromised peripheral circulation. Formal safety profiling for selepressin is pending further trials.

How It Is Administered

Selepressin is administered intravenously, typically as a continuous infusion. Formulations under investigation are intended for use in intensive‑care settings after adequate fluid resuscitation and alongside standard vasopressor therapy.

Routes of Administration

Goals & Uses

• Reduction of norepinephrine requirementsCatecholamine SparingModerate
• Avoidance of V2-mediated adverse effectsSafety Improvement Over VasopressinModerate
• Treatment of vasodilatory/septic shockHemodynamic SupportModerate
• Restoration of vascular tone in distributive shockHemodynamic SupportLow
• Septic shock managementCritical CareModerate

Contraindications

• Known hypersensitivity to selepressin or its excipientsAllergyHigh
• Hypersensitivity to selepressin or vasopressin analoguesAllergyHigh
• Cardiogenic shockCardiovascularHigh
• Severe coronary artery disease or recent myocardial infarctionCardiovascularModerate
• Severe peripheral vascular diseaseVascularHigh

Adverse Effects

• HypertensionCardiovascularCommonHigh blood pressure
• Reduced cardiac outputCardiovascularUncommon
• Digital/mesenteric ischemiaVascularUncommon
• Peripheral ischemia (e.g., mesenteric, digital)VascularUncommon
• HyponatremiaElectrolyteRare
• Skin necrosis at infusion siteDermatologicalRare
• BradycardiaCardiovascularUncommon

Drug Interactions

• Other vasoconstrictors (e.g., norepinephrine, phenylephrine)Moderate
• Indomethacin and NSAIDsModerate
• NorepinephrineModerate
• EpinephrineModerate
• Vasodilators (e.g., nitroglycerin)Low

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Patients with known coronary artery diseaseCardiovascularRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionUnapprovedNo EMA marketing authorization.
• United StatesUnapprovedInvestigational New Drug (IND) status; no FDA approval.
• United KingdomUnapprovedNot licensed by MHRA.

No FDA, EMA, or MHRA approval; studied in Phase II/III trials but development was discontinued after inconclusive efficacy results.

Evidence & Sources

• Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials
  Journal ArticleHighKotani Y, et al.2024-01-01T00:00:00.000000Z
• Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin
  Journal ArticleHighRodriguez R, et al.2020-01-01T00:00:00.000000Z
• Clinical Efficiency of Vasopressin or Its Analogs in Comparison With Catecholamines Alone on Patients With Septic Shock: A Systematic Review and Meta-Analysis
  Journal ArticleHighYao RQ, et al.2020-01-01T00:00:00.000000Z
• Shock - Classification and Pathophysiological Principles of Therapeutics
  Journal ArticleModerateKislitsina ON, et al.2019-01-01T00:00:00.000000Z
• Selepressin in Septic Shock
  Journal ArticleModerateAntonucci E, et al.2022-01-01T00:00:00.000000Z
• Vasopressor therapy in critically ill patients with shock
  Journal ArticleModerateRussell JA2019-01-01T00:00:00.000000Z

Frequently Asked Questions